Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds
Executive Summary
Just moving into Phase II with a pair of candidates, Pfizer trails smaller rivals in the NASH race, but the deep-pocked firm may have the assets to develop its own proprietary combination therapy for the large-scale unmet medical need.
You may also be interested in...
Year Of NASH Upheaval Means Incremental Data At AASLD
With still no approved therapy for non-alcoholic steatohepatitis, Intercept, Madrigal, Inventiva and others used the liver meeting to build the cases for their NASH candidates.
Novartis, Pfizer Advance Their NASH Ambitions Separately, As Partners
Novartis thinks tropifexor may prove to be best-in-class FXR agonist, while Pfizer notes the complementary activity of its ACC and DGAT2 inhibitors. Their NASH trial collaboration is heading toward a Phase II launch in 2020.
Pfizer Thinks First-In-Class KHK Mechanism Could Work For NASH, Diabetes
Pfizer has high hopes for ketohexokinase inhibition and other fat-reducing mechanisms in NASH. Data from a small study reported at EASL also suggest its KHK inhibitor could have utility in diabetes.